At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
Perampaneldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Open-label Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalization
In Brief
A Phase 4 clinical trial evaluating Perampanel for Epilepsy. Completed, enrolled 106 participants across 6 sites.
Detailed Summary
This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionApr 2018
TodayJul 2026
First PostedApr 1, 2016
Enrollment StartMay 3, 2016
Primary CompletionApr 26, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.3 years ago
Interventions
Perampaneldrug